International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update

Joseph F Merola; April W Armstrong; Ami Saraiya; John Latella; Amit Garg; Kristina Callis Duffin; Alice B Gottlieb

doi:10.3899/jrheum.160114

International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update

J Rheumatol. 2016 May;43(5):959-60. doi: 10.3899/jrheum.160114.

Authors

Joseph F Merola¹, April W Armstrong², Ami Saraiya², John Latella², Amit Garg², Kristina Callis Duffin², Alice B Gottlieb²

Affiliations

¹ From Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California; Tufts Medical Center, Boston, Massachusetts; Hofstra North Shore LIJ School of Medicine, Manhasset, New York; University of Utah, Salt Lake City, Utah, USA.J.F. Merola, MD, MMSc, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; A. Saraiya, Tufts Medical Center; J. Latella, International Dermatology Outcome Measures (IDEOM) Patient Research Partner and IDEOM Board of Directors, West Granby, Connecticut, USA; A. Garg, MD, Hofstra North Shore LIJ School of Medicine; K. Callis Duffin, MD, University of Utah; A.B. Gottlieb, MD, PhD, Tufts Medical Center. jfmerola@bwh.harvard.edu.
² From Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California; Tufts Medical Center, Boston, Massachusetts; Hofstra North Shore LIJ School of Medicine, Manhasset, New York; University of Utah, Salt Lake City, Utah, USA.J.F. Merola, MD, MMSc, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; A. Saraiya, Tufts Medical Center; J. Latella, International Dermatology Outcome Measures (IDEOM) Patient Research Partner and IDEOM Board of Directors, West Granby, Connecticut, USA; A. Garg, MD, Hofstra North Shore LIJ School of Medicine; K. Callis Duffin, MD, University of Utah; A.B. Gottlieb, MD, PhD, Tufts Medical Center.

PMID: 27134269
DOI: 10.3899/jrheum.160114

Abstract

Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.

Keywords: IDEOM; OMERACT; OUTCOME MEASURES; PSORIASIS.

MeSH terms

Arthritis, Psoriatic / therapy*
Dermatology*
Humans
Outcome Assessment, Health Care*
Treatment Outcome